Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gemzar Clear all

Conditions: Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: everolimus, gemcitabine hydrochloride, cisplatin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Pancreatic Cancer
Interventions: cetuximab, capecitabine, oxaliplatin, conventional surgery, radiation therapy, Gemcitabine; Biological · Drug · Procedure + 1 more
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dovitinib lactate, gemcitabine hydrochloride, capecitabine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
Interventions: Gemcitabine 1000 mg, nab-paclitaxel, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Bladder Cancer
Interventions: Everolimus and Intravesical Gemcitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Bladder Neoplasms
Interventions: TAR-200; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 9
States / cities: Phoenix, Arizona • Dalton, Georgia • Hanover, Maryland + 5 more

Conditions: Hodgkin's Disease
Interventions: MDX-060; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Duarte, California • Fresno, California • La Jolla, California + 14 more

Conditions: Kidney Cancer
Interventions: cisplatin, gemcitabine hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreatic Adenocarcinoma
Interventions: Gemzar (Gemcitabine), TH-302; Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 59
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 52 more

Conditions: Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Gemcitabine, Hydroxychloroquine, Nab-paclitaxel, Paricalcitol; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Solid Tumor, Lymphoma
Interventions: TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel; Drug
Lead sponsor: Trishula Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Orange, California • Sacramento, California • San Francisco, California + 12 more

Conditions: Cancer,, Solid Tumors, Advanced Solid Malignancies
Interventions: AZD6918, gemcitabine, pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Aurora, Colorado • Nashville, Tennessee

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: carboplatin, gemcitabine, paclitaxel, surgery; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 128
States / cities: Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more

Conditions: Lung Cancer
Interventions: cisplatin, docetaxel, gefitinib, gemcitabine hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases, Adenocarcinoma
Interventions: Paricalcitol (Zemplar); Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
Interventions: Cisplatin, Gemcitabine, ALT-801; Drug · Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more

Conditions: Lung Cancer
Interventions: Gemcitabine, Pemetrexed, Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Solid Tumors, Solid Tumors, Pancreatic Cancer
Interventions: Defactinib, Pembrolizumab, Gemcitabine; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Rochester, Minnesota • St Louis, Missouri

Conditions: Lung Cancer
Interventions: Trastuzumab, Cisplatin, Gemcitabine Hydrochloride; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions: Pemigatinib, Gemcitabine, Cisplatin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Phoenix, Arizona • Greenbrae, California • Orange, California + 29 more

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 38
States / cities: Fullerton, California • Glendale, California • La Jolla, California + 34 more

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Taxotere, Xeloda, Cisplatin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
Interventions: Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel, Docetaxel, Gemcitabine, Etoposide, Irinotecan, Topotecan, Lurbinectedin; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasms
Interventions: RG1507, RO1507, bevacizumab [Avastin], capecitabine [Xeloda], carboplatin, cetuximab, docetaxel, erlotinib [Tarceva], etoposide, gemcitabine, irinotecan, mFOLFOX6, paclitaxel, pemetrexel, sorafenib, temozolomide, trastuzumab [Herceptin]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Tucson, Arizona • San Francisco, California • Santa Monica, California + 5 more

Search by objective public record fields.

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors